Completed PHASE1 INTERVENTIONAL 3-arm NCT02117648

A Study of LY2835219 in Participants With Cancer

Effects of CYP3A Inhibition by Clarithromycin on the Pharmacokinetics of LY2835219 and Its Metabolites in Cancer Patients

Sponsor: Eli Lilly and Company

Conditions Neoplasm Neoplasm Metastasis

Interventions Abemaciclib Clarithromycin

Updated 8 times since 2017 Last updated: Dec 13, 2018 Started: Apr 30, 2014 Primary completion: Feb 28, 2015 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02117648, this PHASE1 trial focuses on Neoplasm and Neoplasm Metastasis and remains completed. Sponsored by Eli Lilly and Company, it has been updated 8 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2019 — Jan 2021 [monthly]

Completed PHASE1
Sep 2018 — Feb 2019 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Sep 2018 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Memphis, United States